Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Details Narrative)

v3.19.3
Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 25, 2019
Mar. 25, 2019
Mar. 25, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Common Stock [Member] | Underwritten Public Offering [Member]                
Number of common stock issued in offering 16,666,668   16,666,668          
Common Stock [Member] | Underwritten Public Offering [Member] | Dr. Frederick Telling [Member]                
Number of common stock issued in offering   100,000            
Common Stock [Member] | Underwritten Public Offering [Member] | Dr. Alan Joslyn [Member]                
Number of common stock issued in offering   66,667            
Short Term Warrants [Member] | Underwritten Public Offering [Member] | Dr. Frederick Telling [Member]                
Number of warrants purchased 50,000 50,000 50,000          
Short Term Warrants [Member] | Underwritten Public Offering [Member] | Dr. Alan Joslyn [Member]                
Number of warrants purchased 33,333 33,333 33,333          
Long Term Warrants [Member] | Underwritten Public Offering [Member] | Dr. Frederick Telling [Member]                
Number of warrants purchased 50,000 50,000 50,000          
Long Term Warrants [Member] | Underwritten Public Offering [Member] | Dr. Alan Joslyn [Member]                
Number of warrants purchased 33,333 33,333 33,333          
Intrexon [Member]                
Accounts payable and accrued expenses       $ 55,771   $ 55,771   $ 39,607
Percentage of outstanding common stock       3.36% 8.30% 3.36% 8.30%  
Intrexon [Member] | Oral Mucositis and Lantibiotic Exclusive Channel Collaboration Agreements [Member]                
Cash paid to related parties       $ 134,635 $ 134,883 $ 251,946 $ 294,116